Paratek Pharmaceuticals, Inc. (PRTK)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

1.9300

+0.0400

(+2.12%)

At close: 04:00PM EDT

1.9200

-0.01

(-0.52%)

Pre-Market:

07:00AM EDT

Loading interactive chart...

Thomson Reuters StreetEvents
Q4 2022 Paratek Pharmaceuticals Inc Earnings Call
Q4 2022 Paratek Pharmaceuticals Inc Earnings Call
Zacks
Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of -1,300% and 33.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax Programs BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2022. Paratek gene